
Keywords: ACE-I; angiotensin-converting-enzyme inhibitors; ALP; alkaline phosphatase; ARBs; angiotensin 2 receptor blockers; BMI; body mass index; CKD-EPI; chronic kidney disease epidemiology collaboration; CVD; cardiovascular disease; ESRD; end stage renal disease